<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>Baqiyatallah University of Medical Sciences</PublisherName>
				<JournalTitle>Journal of Applied Biotechnology Reports</JournalTitle>
				<Issn>2322-1186</Issn>
				<Volume>12</Volume>
				<Issue>3</Issue>
				<PubDate PubStatus="epublish">
					<Year>2025</Year>
					<Month>09</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Optimizing Heterologous Expression of CYP124 in Escherichia coli using Box-Behnken Design</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>1746</FirstPage>
			<LastPage>1753</LastPage>
			<ELocationID EIdType="pii">232253</ELocationID>
			
<ELocationID EIdType="doi">10.30491/jabr.2024.470675.1766</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Catherine Marta</FirstName>
					<LastName>Gunawan</LastName>
<Affiliation>Laboratory of Combinatorial Biosynthesis, Department of Pharmaceutical Biology, School of Pharmacy, Institut Teknologi Bandung, Jalan Ganesha No. 10 Bandung, West Java 40132, Indonesia</Affiliation>

</Author>
<Author>
					<FirstName>Masyarrah Halida</FirstName>
					<LastName>Nurfadila</LastName>
<Affiliation>Laboratory of Combinatorial Biosynthesis, Department of Pharmaceutical Biology, School of Pharmacy, Institut Teknologi Bandung, Jalan Ganesha No. 10 Bandung, West Java 40132, Indonesia</Affiliation>

</Author>
<Author>
					<FirstName>Ratna Annisa</FirstName>
					<LastName>Utami</LastName>
<Affiliation>Laboratory of Pharmaceutical Biotechnology, Department of Pharmaceutics, School of Pharmacy, Institut Teknologi Bandung, Jalan Ganesha No. 10 Bandung, West Java 40132, Indonesia</Affiliation>
<Identifier Source="ORCID">0000-0002-5660-9961</Identifier>

</Author>
<Author>
					<FirstName>Hegar</FirstName>
					<LastName>Pramastya</LastName>
<Affiliation>Laboratory of Combinatorial Biosynthesis, Department of Pharmaceutical Biology, School of Pharmacy, Institut Teknologi Bandung, Jalan Ganesha No. 10 Bandung, West Java 40132, Indonesia</Affiliation>
<Identifier Source="ORCID">0000-0002-4585-219X</Identifier>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2024</Year>
					<Month>07</Month>
					<Day>30</Day>
				</PubDate>
			</History>
		    <Abstract>Introduction: CYP124 is a cytochrome P450 enzyme from Mycobacterium tuberculosis capable of catalyzing ω-hydroxylation of methyl-branched lipids, isoprenoid alcohols, sterols, cholesterol analogs, and vitamin D3. It is also suspected to be involved in the bacterium&#039;s resistance to macrophages. Due to its capabilities, CYP124 has potential as a drug target and biocatalyst. Therefore, there is a need to produce sufficient quantities of CYP124 for biochemical assays, protein engineering, and drug development. The study optimized CYP124 production in Escherichia coli DH5α using Response Surface Methodology (RSM) with a Box-Behnken Design (BBD). 
Materials and Methods: FeCl3, δ-aminolevulinic acid (5-ALA), and IPTG concentrations were optimized using BBD. A total of 15 experimental runs with various factor combinations were performed, and a three-dimensional response surface was generated to analyze the effects and identify the optimal concentrations of each factor, with R/Z value and CYP124 yield as responses. 
Results: The optimal supplement combination for CYP124 production included 0.10 mM FeCl3, 1 mM 5-ALA, and 0.2427 mM IPTG. The model predicted the highest CYP124 yield to be 0.041 mg/L. Purified CYP124 bound to farnesol, its substrate, with a dissociation constant of 1.00 ± 0.14 µM. 
Conclusions: The findings underscore the significance of ALA supplementation in regulating CYP450 expression and emphasize the need to optimize FeCl3 and IPTG concentrations as cofactors and inducers, respectively. </Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Cytochrome P450</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Medium Supplements</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Response Surface Methodology</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Mycobacterium tuberculosis</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://www.biotechrep.ir/article_232253_a7ef3d50041a3a89927c0ce7e918834a.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
